TY - JOUR
T1 - The effect of homocysteine reduction by B-vitamin supplementation on markers of endothelial dysfunction
AU - Peeters, Anita C.T.M.
AU - van der Molen, Els F.
AU - Blom, Henk J.
AU - den Heijer, Martin
PY - 2004/11
Y1 - 2004/11
N2 - Hyperhomocysteinemia is a risk factor for arterial vascular disease and venous thrombosis. The pathophysiology of this relation is unclear, but several studies suggest that hyperhomocysteinemia impairs endothelial function. We examined the effect of homocysteine lowering by B-vitamin supplementation on tissue plasminogen activator (tPA), plasminogen activator inhibitor type I (PAI) and von Willebrand factor (vWf) - markers of endothelial dysfunction - in hyperhomocysteinemic and normohomocysteinemic volunteers. A total of 123 healthy volunteers were randomized to placebo or B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks. Before and after the intervention period, blood samples were taken for measurements of homocysteine, tPA, PAI and vWf. There was no evident association between homocysteine concentration and concentrations of markers of endothelial dysfunction at baseline. The mean reduction of homocysteine concentration was 31% (95%CI 22.7 to 39.1) in the B-vitamin group compared to 3% reduction in the placebo group. Concentrations of tPA, PAI and vWf did not change after supplementation of B-vitamins. In conclusion, the results of our study show that homocysteine reduction by B-vitamin supplementation has no effect on markers of endothelial dysfunction in healthy volunteers.
AB - Hyperhomocysteinemia is a risk factor for arterial vascular disease and venous thrombosis. The pathophysiology of this relation is unclear, but several studies suggest that hyperhomocysteinemia impairs endothelial function. We examined the effect of homocysteine lowering by B-vitamin supplementation on tissue plasminogen activator (tPA), plasminogen activator inhibitor type I (PAI) and von Willebrand factor (vWf) - markers of endothelial dysfunction - in hyperhomocysteinemic and normohomocysteinemic volunteers. A total of 123 healthy volunteers were randomized to placebo or B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks. Before and after the intervention period, blood samples were taken for measurements of homocysteine, tPA, PAI and vWf. There was no evident association between homocysteine concentration and concentrations of markers of endothelial dysfunction at baseline. The mean reduction of homocysteine concentration was 31% (95%CI 22.7 to 39.1) in the B-vitamin group compared to 3% reduction in the placebo group. Concentrations of tPA, PAI and vWf did not change after supplementation of B-vitamins. In conclusion, the results of our study show that homocysteine reduction by B-vitamin supplementation has no effect on markers of endothelial dysfunction in healthy volunteers.
KW - Endothelial dysfunction
KW - Hyperhomocysteinemia
KW - Plasminogen activator inhibitor type 1
KW - Tissue plasminogen activator and von Willebrand factor
UR - http://www.scopus.com/inward/record.url?scp=9144273289&partnerID=8YFLogxK
U2 - https://doi.org/10.1160/TH04-05-0284
DO - https://doi.org/10.1160/TH04-05-0284
M3 - Article
C2 - 15543337
SN - 0340-6245
VL - 92
SP - 1086
EP - 1091
JO - Thrombosis and haemostasis
JF - Thrombosis and haemostasis
IS - 5
ER -